HSPG2 and cancer: Our proposition is that while low CDS1 expression increases susceptibility to loss of cellular fitness from CDS2 disruption, the true extent of CDS2 dependency may be influenced by cell type and tumor-specific biological factors such as degree of chronic PLC activity, resulting in a viable therapeutic avenue for further investigation in cancers.